Arguello, Alexandra M.
Till, Sara E.
Reinholz, Anna K.
Okoroha, Kelechi R.
Barlow, Jonathan D.
Camp, Christopher L. https://orcid.org/0000-0003-3058-7327
Article History
Accepted: 25 September 2022
First Online: 12 October 2022
Declarations
:
: Christopher L. Camp has received personal fees and non-financial support from Arthrex, personal fees and non-financial support from Zimmer Biomet, non-financial support from Stryker Corporation, and personal fees from Gemini Inc. Jonathan D. Barlow has received personal fees, non-financial support, and other from Arthrex; personal fees and other from Stryker Corporation; personal fees and other from Zimmer Biomet Holdings Inc.; and personal fees from DePuy Synthes Sales Inc. Kelechi R. Okoroha has received grants, personal fees, and other from Arthrex; personal fees and other from Stryker Corporation; personal fees and other from Zimmer Biomet Holdings Inc.; personal fees from Medical Device Business Services Inc.; personal fees from Smith & Nephew, Inc.; personal fees from Medtronics USA, Inc.; personal fees from Wright Medical Technology, Inc.; personal fees from Lilly USA, LLC; other from Pinnacle, Inc.; other from Medwest Associates; personal fees from Bioventus LLC; personal fees from Vericel Corporation; and other from Endo Pharmaceuticals, Inc. Alexandra M. Arguello, Sara E. Till, and Anna K. Reinholz declare that they have no conflict of interest.
: All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).